Harrow Health (NASDAQ:HROW) Given New $34.40 Price Target at LADENBURG THALM/SH SH

Harrow Health (NASDAQ:HROW – Free Report) had its price objective upped by LADENBURG THALM/SH SH from $33.70 to $34.40 in a report published on Thursday morning, FlyOnTheWall reports. HROW has been the subject of a number of other research reports. B. Riley upped their price target on Harrow Health from $42.00 to $45.00 and gave […]

Related Keywords

,Blackrock Inc ,Surface Ophthalmics Inc ,Harrow Health ,News Ratings For Harrow Health Daily ,Harrow Health Stock Performance ,Harrow Health Inc ,Eton Pharmaceuticals Inc ,Wasatch Advisors Inc ,Pharmaceuticals Inc ,Prelude Capital Management ,Hedge Funds Weigh In On Harrow Health ,Envestnet Asset Management Inc ,Free Report ,Street Capital ,Get Free Report ,Asset Management ,Capital Management ,State Street Corp ,Street Corp ,Surface Ophthalmics ,Melt Pharmaceuticals ,Eton Pharmaceuticals ,Harrow Health Daily ,Nasdaq Hrow ,Throw ,Medical ,Boost Price Target ,Ladenburg Thalm Sh ,